Skip to main content

Gilead paying $5.1 billion to increase its stake in Belgian biotech Galapagos

Gilead Sciences Inc. will pay $5.1 billion to boost its stake in Galapagos NV and gain rights outside Europe to the Belgian biotechnology company’s treatments in development, in a broad research collaboration aimed at increasing growth at the drugmakers.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.